Ibudilast for Treating Alcohol Use Disorder (NCT05414240)
A Randomized, Double-blind Placebo-Controlled Study of Ibudilast for Treating Alcohol Use Disorder
🩺 Plain-English Summary (8th-Grade Level)
This is a research study involving 6 weeks of study medication, Ibudilast or a placebo (an inactive substance) and medical management counseling to reduce or stop drinking. Ibudilast is not approved by the U.S. FDA for clinical use in the United States, but it is has been used for many years in Japan for its anti-inflammatory effects. Its use in the treatment of alcohol dependence is experimental. By reducing inflammation, Ibudilast may help some people reduce or stop drinking. We have obtained an Investigational New Drug Application (IND) approval for this study from the FDA. Ibudilast has been used clinically for 20 years in Asia for treating bronchial asthma and, more recently, for post-stroke dizziness and ocular allergies and has been shown to be safe and well tolerated.
Who can join: Review the eligibility criteria below.
Location: University of Pennsylvania Center for Studies of Addiction — Philadelphia, Pennsylvania
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Pennsylvania Center for Studies of Addiction — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Alcohol Use Disorder (AUD)
- PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD) — Seattle, Washington
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study — Spokane, Washington
- Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes — New Haven, Connecticut
- Social Identity Mapping for Adolescent Recovery — Boston, Massachusetts
- Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving — Baltimore, Maryland
Explore by condition: All Alcohol Use Disorder (AUD) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.